Molina-Granada, David
González-Vioque, Emiliano
Dibley, Marris G.
Cabrera-Pérez, Raquel
Vallbona-Garcia, Antoni
Torres-Torronteras, Javier
Sazanov, Leonid A. http://orcid.org/0000-0002-0977-7989
Ryan, Michael T.
Cámara, Yolanda http://orcid.org/0000-0003-2458-6942
Martí, Ramon http://orcid.org/0000-0002-8273-9540
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (GNT1164459)
Ministry of Economy and Competitiveness | Agencia Estatal de Investigación (BFU2014-52618-R, SAF2017-87506, PID2020-112929RB-I00)
Article History
Received: 24 February 2022
Accepted: 8 June 2022
First Online: 23 June 2022
Competing interests
: The authors declare the following competing interests: R.M. and Y.C. report grants and non-financial support from Modis Therapeutics, personal fees and other from Modis Therapeutics, outside the submitted work. RM and YC have a patent “Treatment of mitochondrial diseases” (PCT/ EP2016/062636) with royalties paid by Modis Therapeutics. RM has a patent “Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes” (PCT/US16/038110) with royalties paid by Modis Therapeutics. These relationships are <i>de minimus</i> for Vall d’Hebron Research Institute and CIBERER. The other authors report no conflict of interests.